Semi-classical limit and minimum decoherence in the Conditional Probability Interpretation of Quantum Mechanics

The Conditional Probability Interpretation of Quantum Mechanics replaces the abstract notion of time used in standard Quantum Mechanics by the time that can be read off from a physical clock. The use of physical clocks leads to apparent non-unitary and decoherence. Here we show that a close approximation to standard Quantum Mechanics can be recovered from conditional Quantum Mechanics for semi-classical clocks, and we use these clocks to compute the minimum decoherence predicted by the Conditional Probability Interpretation.Comment: 8 pages, references adde

Searching the Higgs with the Neurochip TOTEM

We show that neural network classifiers can be helpful in discriminating Higgs production events from the huge background at LHC, assuming the case of a mass value $M_H \sim 200$ GeV. We use the high performance neurochip TOTEM, trained by the Reactive Tabu Search algorithm (RTS), which could be used for on-line purposes. Two different sets of input variables are compared.Comment: 4 pages,1 figure, requres espcrc2.sty and epsfig.sty. Work prsented in The 5th Topical Seminar on ``The irresistible rise of the Standard Model'', San Miniato, Tuscany, Italy, April 21-25 199

Gaussian quantum operator representation for bosons

We introduce a Gaussian quantum operator representation, using the most general possible multimode Gaussian operator basis. The representation unifies and substantially extends existing phase-space representations of density matrices for Bose systems and also includes generalized squeezed-state and thermal bases. It enables first-principles dynamical or equilibrium calculations in quantum many-body systems, with quantum uncertainties appearing as dynamical objects. Any quadratic Liouville equation for the density operator results in a purely deterministic time evolution. Any cubic or quartic master equation can be treated using stochastic methods

Carcinogenic Effects in a Phenylketonuria Mouse Model

Phenylketonuria (PKU) is a metabolic disorder caused by impaired phenylalanine hydroxylase (PAH). This condition results in hyperphenylalaninemia and elevated levels of abnormal phenylalanine metabolites, among which is phenylacetic acid/phenylacetate (PA). In recent years, PA and its analogs were found to have anticancer activity against a variety of malignancies suggesting the possibility that PKU may offer protection against cancer through chronically elevated levels of PA. We tested this hypothesis in a genetic mouse model of PKU (PAHenu2) which has a biochemical profile that closely resembles that of human PKU. Plasma levels of phenylalanine in homozygous (HMZ) PAHenu2 mice were >12-fold those of heterozygous (HTZ) littermates while tyrosine levels were reduced. Phenylketones, including PA, were also markedly elevated to the range seen in the human disease. Mice were subjected to 7,12 dimethylbenz[a]anthracene (DMBA) carcinogenesis, a model which is sensitive to the anticancer effects of the PA derivative 4-chlorophenylacetate (4-CPA). Tumor induction by DMBA was not significantly different between the HTZ and HMZ mice, either in total tumor development or in the type of cancers that arose. HMZ mice were then treated with 4-CPA as positive controls for the anticancer effects of PA and to evaluate its possible effects on phenylalanine metabolism in PKU mice. 4-CPA had no effect on the plasma concentrations of phenylalanine, phenylketones, or tyrosine. Surprisingly, the HMZ mice treated with 4-CPA developed an unexplained neuromuscular syndrome which precluded its use in these animals as an anticancer agent. Together, these studies support the use of PAHenu2 mice as a model for studying human PKU. Chronically elevated levels of PA in the PAHenu2 mice were not protective against cancer

Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine

Aims To assess whether cystatin C, a new serum marker of renal function, is a better index of creatinine or digoxin clearance than serum creatinine in older people. Methods Twenty-two volunteers over the age of 65 years (mean 73 +/- 5) were recruited from a healthy elderly volunteer database. None of the volunteers was taking digoxin or other medication known to interfere with digoxin kinetics or assay. Digoxin was infused at a dose of 7-10 mug kg(-1) and blood samples were taken over the following 48 h and assayed for serum digoxin. Serum cystatin C, creatinine and creatinine clearance were measured and a calculated creatinine clearance was estimated using the Cockcroft Gault formula. Digoxin clearance was calculated using a pharmacokinetic software package. All values were log transformed to normalize their distribution. Results. Of the 22 volunteers enrolled into the study, 18 completed the study. Serum cystatin C ranged between 0.72 and 1.89 mg 1(-1) and serum creatinine ranged from 69.0 to 153.9 mumol 1(-1). Measured creatinine clearance ranged from 38 to 23 ml min(-1) and calculated creatinine clearance from 29.5 to 88.0 ml min(-1). Digoxin clearance ranged from 51.0 to 103.5 ml min(-1). Cystatin C correlated extremely well with creatinine (r=0.93,